Zero PFOA PTFE
Management in 2014
As diagnostics technology continues to help move healthcare toward
truly individualized treatment, identifying specific conditions in patients
is critical. In the cardiovascular space, nuclear magnetic resonance tech-
nology is impacting LDL related cardiovascular disease management.
This article looks at the technology.
By Deanna Franke, Ph.D., MT(ASCP),
DABCC, Clinical Laboratory Director,
Emerging at the forefront of LDL-re- lated (low density lipoprotein) cardiovascular disease management
is nuclear magnetic resonance (NMR), a
technology that is quickly being adopted by
physicians across the country and changing
the standard of care in LDL management.
Traditionally, the cholesterol content of
LDL (LDL-C) has been used to estimate
circulating LDL levels. However, the
cholesterol content of LDL varies widely
among individuals and is often dependent
on the metabolic state of the subject whose
sample is being evaluated. An alternate
measure of LDL quantity – LDL particle
number (LDL-P) via nuclear magnetic res-
onance (NMR) spectroscopy – is unaffect-
ed by changes in cholesterol content. As
a result of varying amounts of cholesterol
contained in LDL, frequent discordance
(disagreement in alternate measures) is
noted between LDL-C and NMR LDL-P.
The Vantera Clinical Analyzer offers the
only FDA-cleared technology that has
the ability to directly enumerate LDL